Gland Pharma Limited has announced its consolidated financial results for the quarter and year ending March 31, 2026, showcasing significant growth in both total income and net profit.
The company has also recommended a final dividend for its shareholders.
In the March 2026 quarter, Gland Pharma's total income increased by 26.2% year-on-year (YoY) to ₹1,854.26 crore, compared to ₹1,468.94 crore in the same quarter the previous year.
This also represents a 5.4% quarter-on-quarter (QoQ) rise from ₹1,758.54 crore in the December 2025 quarter.
The company's net profit (PAT) saw a substantial 96.6% YoY increase, reaching ₹366.68 crore, up from ₹186.54 crore a year earlier.
On a QoQ basis, net profit rose by 40.2% from ₹261.48 crore in the December 2025 quarter.
For the full financial year 2025-26, Gland Pharma reported a 15.7% YoY increase in total income, amounting to ₹6,746.98 crore, up from ₹5,830.11 crore in FY25.
The net profit for FY26 surged by 47.1% YoY to ₹1,027.32 crore, compared to ₹698.53 crore in the previous financial year.
Read More: Alembic Pharma Share in Focus After USFDA Tentative Approval for Generic Prostate Cancer Drug!
Gland Pharma has recommended a final dividend of ₹20 (2,000%) per equity share of ₹1 each for the financial year 2025-26.
The dividend will be paid within 30 days from the date of the 48th Annual General Meeting (AGM), subject to shareholder approval.
The record date for determining the eligibility of shareholders to receive the dividend is set for August 11, 2026.
As of May 18, 2026, at 11:57 AM, Gland Pharma share price on NSE was trading at ₹2,139.80 up by 14.53% from the previous closing price.
Gland Pharma's financial results for Q4 and FY26 reflect a strong performance, with significant increases in both income and net profit. The proposed dividend underscores the company's commitment to delivering value to its shareholders.
Read stock market news in Hindi. Head to Angel One's share market news in Hindi for comprehensive coverage.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 18, 2026, 12:25 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
